Calidi Biotherapeutics Q2 FY26 net loss narrows 26.32% to $4.2 million; general and administrative expense drops 48% to $1.6 million - CLDI News | Rallies
Calidi Biotherapeutics Q2 FY26 net loss narrows 26.32% to $4.2 million; general and administrative expense drops 48% to $1.6 million C CLDI • 2026-08-13 Cash position and pipeline update
Cash was $4.1 million at June 30, down from $5.6 million at Dec. 31, with $0.2 million restricted cash.
FDA pre-IND feedback backed the CLD-401 strategy, with first patient dosing targeted for Q1 2027 , CEO Eric Poma said.
Q2 FY26 loss narrows as G&A expense declines
Calidi Biotherapeutics posted a net loss attributable to common stockholders of $4.2 million , or $2.94 a share , in Q2 2026.
Loss narrowed from $5.7 million a year earlier, while research and development expense held at $2.6 million .
General and administrative expense fell 48% to $1.6 million , reflecting a $1.5 million reduction versus Q2 2025.
2026-08-13
CLDI•
